Search results for New England Journal of Medicine
Industry
Lilly\'s next-generation obesity drug retatrutide shows 25 percent weight loss in 80 weeks
Eli Lilly\'s next-generation obesity drug candidate retatrutide showed an average 25 percent weight loss at the highest dose after 80 weeks in a Phase 3 trial. Among participants who extended treatment to 104 weeks, average weight loss rose to 30 percent. Results were published in the New England Journal of Medicine, with more than one-third losing at least 30 percent of body weight. The study did not directly compare retatrutide with existing obesity drugs, and researchers said further trials are needed.
Industry
Hantavirus fears revive COVID-19 beneficiary stocks; Moderna and BioNTech in focus
Rising concerns about a possible spread of hantavirus are pushing medical and vaccine-related stocks back into focus after gaining attention during the COVID-19 pandemic. BeInCrypto reported that Moderna, Emergent BioSolutions and BioNTech entered reassessment phases in May. Moderna shares rose on stronger first-quarter sales, vaccine cooperation news and flu vaccine trial data publication. Emergent is focused on confirming a bottom amid weaker guidance. BioNTech faces a bearish technical pattern despite maintained revenue guidance.
AI & Enterprise
AI sales concentration deepens as AI-native firms seek to diversify beyond subscriptions
Revenue at AI-native companies selling AI models or services is rising, but sales are heavily concentrated. OpenAI and Anthropic account for nearly 85 percent of annualised revenue among the top 10, and the top 10 reach 94 percent combined. Some apps have passed annualised revenue milestones, and ad-based models are emerging. OpenEvidence sells chatbot ads to doctors and drugmakers. Despite growth, uncertainty persists as many firms remain loss-making and face competition from model providers.